GLA and Fabry disease: The BRIDGE study (completed in December 2019) was a Phase 3, open-label switch-over study of the safety and efficacy of pegunigalsidase alfa at the dose of 1 mg/kg every other week in adult patients with Fabry disease having previously been treated with agalsidase alfa for two or more years and a stable dose of the latter for at least the last 6 months (Linhart et al., 2023).